Tagged with S

China EpimAb Biotherapeutics’ Chengbin Wu explains why the expansion of bispecifics into solid tumors and autoimmune diseases marks a major therapeutic turning point. He outlines how, through rational antibody engineering and unique molecule formats, EpimAb has differentiated itself with safer, more effective therapies than its competitors, as well as how the…

Puerto Rico Dr. Eduardo Nicolau shares his journey from being a professor of chemistry to becoming Executive Director of the MSRC in 2021. His leadership focuses on financial stability, creating a biotech incubator, and establishing key partnerships with the industry, including a significant collaboration with the biotechnology company CytoImmune Therapeutics for cancer…

Puerto Rico Ella Woger-Nieves of Invest Puerto Rico highlights the island’s remarkable evolution into a global pharmaceutical manufacturing, life sciences, and innovation hub. Woger-Nieves explains how, over the past five years, Puerto Rico has expanded its capabilities in research and development, fostered collaboration between startups and legacy companies, and positioned itself as…

Puerto Rico Arthur Deboeck is a chemical engineer with more than 50 years of expertise in the domain of drug delivery systems, having pioneered innovations such as the first extended-release once-a-day drug exempt from food effect. He founded his own company in Puerto Rico (Galephar) in 1986, focusing on R&D for difficult…

Mexico Some 16 percent of Mexico’s population is battling diabetes—a number that represents one in five of the nation’s populace without including the vast numbers of undiagnosed Mexicans living with the disease. The new Mexican government has committed to reducing the burden of diabetes by stepping up primary care and preventive…

China A roundup of some of the biggest stories coming out of China’s pharma industry, including the new drugs added to the country’s national health insurance with AstraZeneca’s breast cancer blockbuster, Enhertu, among them; the launch of Novo’s Wegovy in China; Eli Lilly’s obesity partnership with Hong Kong-listed Laekna; Merck’s cancer…

China Vincent Chan, VP and GM of bioMérieux Greater China, shares insights into how the microbiology diagnostics company’s presence has evolved in China over the course of 30 years to today serve some 4,000 hospitals across the country. He walks us through the government measures that have prioritized microbiology testing to…

China Shawn Xiang, corporate officer and China head at Santen, discusses the eye care specialist’s second-largest market and the challenges of diagnosing and managing eye conditions in China where a lack of public awareness is coupled with the country’s shortage of clinical capacity in ophthalmology. He remarks on Santen’s “China 2.0”…

Mexico Victor Matos, Senior Commercial Director at Johnson & Johnson MedTech in Mexico, shares insights about his first days as a Managing Director, highlighting the importance of connecting the company’s objectives with Mexico’s diverse healthcare system. He emphasises J&J’s significant local footprint, with major commercial and manufacturing operations including a key…

Switzerland Matteo Boggi, General Manager of Fresenius Kabi Switzerland, shares insights into the company’s pivotal role in supporting healthcare professionals as well as critically and chronically ill patients across Switzerland. Boggi highlights Fresenius Kabi’s extensive portfolio in nutrition, medical devices, generic drugs, and biosimilars, while discussing the company’s innovative strategies and…

Switzerland Dominik Escher, Managing Partner of Pureos Bioventures explores the firm’s strategic focus on drug development, particularly in biologics and antibody-based therapeutics. With a keen emphasis on the Swiss biotech ecosystem, Escher discusses the firm’s investment approach and its commitment to fostering innovation in Europe and beyond.   Swiss biotech stands…

Switzerland Emanuele Ostuni, CEO of ARTBIO, delves into the company’s innovative approach to radioligand therapies, focusing on its potential to replace chemotherapy and provide more effective treatment options for patients. Ostuni emphasizes the company’s commitment to precision oncology, with a strong team spread across Switzerland, Norway, USA, and the UK.  …